

Decision Support for Solubilization is now available in ZoomLab[™]

Poorly soluble drugs for oral administration present unique formulation challenges, particularly during early development. ZoomLab[™]'s "Decision Support for Solubilization" module helps formulators evaluate whether amorphous solid dispersions or lipid-based formulations are suitable dosage forms for your active ingredient!

ZoomLab[™]'s "Decision Support for Solubilization" module evaluates several parameters relevant for the structured development of poorly soluble drugs. Based on user-input experimental and computed properties, guidance on the following aspects is given:

- Estimated solubility in lipids
- Expected glass-forming ability
- Attainable drug load in solid dispersions
- Suitable formulation type based on classification algorithms
- Formulation examples of similar active ingredients

Based on the recommended formulation type, ZoomLab[™] provides the user with further advice on subsequent formulation development.

Find the new **"Decision Support for Solubilization"** module on **ZoomLab[™]'s homepage** with the Solubilization modules.

Discover for yourself how fast and easy it is to formulate with ZoomLab[™] by signing up today – for free! Just enter a few physiochemical properties of the active ingredient and the target dosage form and let ZoomLab[™] take care of the rest.

https://info-mypharma.basf.com/



A ZoomLab ¹¹¹ MyProductWorld RegXcellence	8 Projects Produ	ct Development 🗸	Knowledg	e Base 🗸						a 0	
ZoomLab [™] → ZoomLab 2.4 → Decision Support for So											
Decision Support for So Decision Support for So		ion							© Hr		
Decision Support for S	olubilizat								011	~	
Project Details		Ξ		Evaluation	n of Formu	lation Stra	tegies			Θ	
Project name (leave blank for default name)							Resu	It			
ZoomLab 2.4			Estimat	ed solubility i	n soybean oil		52.3 (re's			
+ Properties of Active Ingredient		Θ		ed glass-form			poor				
Active ingredient (leave blank for new active ingredient)			Proposed formulation (logistic regression model)					Lipid-based formulation			
Ibuprofen 50	~	Load data	Share o	f solid disper	sions (logistic	regression mo	3el) 11.33				
Welling point (°C) *		0	Proposi	d formulation	decision tree	a model)	Lipid-	based form	nulation		
	76.0		Share o	f solid disper	sions (decision	tree model)	0.0%				
3lass transition temperature (°C)	-45.0		Based or	molecular d	escriptors and	comparison w	th available dr	ug produc	is, the logistic		
Molecular properties of the active ingredient (enter value	is or import data from	PubChem)	regressic	n model prop	oses formulati	ing the active i	rgrectient as a	lipid-base	i system. The		
Q. CAS registry no., chemical name, monograph na	ne, or synonym	Search	molecula	descriptors,	the algorithm	has identified	he top 10 mos	t similar ar	tive ingredie	nts.	
Violecular weight (grmol) *	206.2	0	molecule	s are exclusiv	ules are exclu vely formulated	l as lipid-base	systems. The	refore, for	mulating the i		
Number of hydrogen bond acceptors *					phous solid die on the perfor					and ac	
lumber of hydrogen bond donors *	-				s recommend		rein, ronnun	ing the is	ure sigreen		
lumber of nitrogen atoms		•	Kost Similar Drug Products								
lumber of rotatable bonds *			Achievable Drug Loading in Solid Dispersions								
Number of non-aromatic double bonds *			<u>ilit</u> i	Achievabl	e Drug Los	ading in So	did Disper	sions		E	
Number of aromatic six-membered rings *		U	1.6 -				_				
		0		Low drug k	oading (< 35%) X)					
Computed partition coefficient (XLOGP3) *	3.5	• 😮	1.5 -								
Fopological polar surface area (A ^a) *	37.3	0	1.4 -	Moderate o	irug loeding (3	5% - 50%)					
lansen solubility parameters calculated by the van Kre-	elen method (MPa ^{0.5})		F0 1.3 -								
Contribution from dispersion forces (6d)	17.8	6	⊨ ²	High doug l	oading (> 50%						
Contribution from dipolar intermolecular force (õp)	22	à	1.2 -								
Contribution from hydrogen bands (Rh)	7.1		1.1 -								
	7.1	,	1 -								
S Finished				D	ż	4	é ogP	8	10	12	
Ŷ.	13		1.4). As a expected dried soli applied b	result, the m to be less th dispersions solid disper- solid disper- solid disper- solid disper- tempt and the solid such as soly a such as soly a in glycorides . If a suitable issed (e.g., Pl residered. If it	Imperature of the accimum achies an 35%. Piese with HPMCAI shors in general ntary Infor ntary Infor ntary Infor advice abors, a syste abors, a syste	vable drug foa e note that the 3. However, it is is matic develops tai combinati d to the espect of (IDDOS, are via s based on po vent mixture is is to resid data	ding in an amo classification is a expected the nent approach institution of the statistic options () yethylone give identified, from ension) or mice is identified, from ension) or mice	ephous so is based o it the record is record the active ageneral the active aged syste of or prop subting the ellar syste mulating	Id dispersion n data from a mmendations rended due 5 rule, the targ ingredient in mms with high UTHIA). If th dens glycol s e active ingre	is proy- can be e o the set dent a build mark a build mark a call a ca	

Register for a Webinar with Pharma Excipients and BASF

ZoomLab[™]: Digitally guiding dosage form and formulation for improved solubility

Tuesday, June 8th, 2021 9AM EST | 3PM CET

Register at: https://lnkd.in/d7ZhGJ6